AstraZeneca AZN today announced the results of a Phase III long-term
safety and tolerability study of the once-daily 25mg dose of naloxegol, in
patients with non-cancer pain and opioid-induced constipation (OIC). Naloxegol
is an investigational peripherally-acting mu-opioid receptor antagonist
(PAMORA), which has been studied in OIC in adult patients with chronic
non-cancer pain, a common condition caused by prescription opioid pain
medicines. Data were presented at the American College of Gastroenterology
(ACG) 2013 Annual Scientific Meeting in San Diego, California.
The Phase III study, KODIAC-08 (n=844), was a 52-week, long-term safety trial
of naloxegol (n=534) vs. usual care (n=270) in patients with non-cancer
related pain and OIC. Usual care was defined as the investigator's choice of
an existing laxative treatment regimen for OIC.
“The data from the long-term safety study further support the safety and
tolerability of naloxegol, a PAMORA which could help address an unmet need for
millions of patients with OIC.” said Kathleen Cantagallo, Clinical VP,
naloxegol, AstraZeneca.
Data from KODIAC-08 reinforces the safety and tolerability findings from
previous Phase III studies, KODIAC-04 and -05. Data from KODIAC-08 included:
* Most naloxegol-emergent gastrointestinal adverse events (AEs) occurred
early in treatment and were transient with 9 patients (1.6%) discontinuing
naloxegol due to abdominal pain;
* Most common treatment-emergent AEs occurring more often with naloxegol vs.
usual care were abdominal pain (17.8% vs. 3.3%), diarrhoea (12.9% vs.
5.9%), nausea (9.4% vs. 4.1%), headache (9.0% vs. 4.8%), and flatulence
(6.9% vs. 1.1%);
* There were no imbalances seen in the independently adjudicated
cardiovascular events between the two groups - 2 patients in each arm of
the study had major adverse cardiovascular events (MACE) and these events
were not attributed to study drug;
* There were two opioid withdrawal AEs reported in patients taking naloxegol
(both were attributed to decreases or discontinuation of opioid medication
and both were deemed unrelated to treatment with naloxegol);
* Pain scores and opioid doses were comparable between treatment groups and
were stable throughout the study;
* No bowel perforations occurred in either group of the study.
In addition to the new safety data for naloxegol presented at the 2013
American College of Gastroenterology (ACG) Meeting, there are two additional
data presentations for naloxegol at the meeting:
* Tuesday, October 15, Plenary Session 2: Endoscopy/Functional Bowel
Disorders; Chey et. al. “Naloxegol Symptom Responder Rates in Patients
With
Opioid-Induced Constipation: Results From 2 Prospective Randomized
Controlled Trials”
* Tuesday, October 15, Poster Session: “Chey et. al., “Efficacy of Naloxegol
in a Subpopulation of Patients With Opioid-Induced Constipation and an
Inadequate Baseline Response to Laxatives: Results From 2 Prospective,
Randomized, Controlled Trials”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in